Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 67 President Street, MSC861, Charleston, SC 29425, USA.
Nicotine Tob Res. 2012 Feb;14(2):234-9. doi: 10.1093/ntr/ntr130. Epub 2011 Jul 20.
Despite tremendous potential public health impact, little work has focused on development of evidence-based smoking cessation treatments for adolescents, including pharmacotherapies. No prior studies have explored the feasibility and safety of varenicline and bupropion XL, 2 potentially promising pharmacotherapies, as smoking cessation treatments in adolescents.
Treatment-seeking older adolescent smokers (ages 15-20) were randomized (double-blind) to varenicline (n = 15) or bupropion XL (n = 14), with 1-week titration and active treatment for 7 weeks. Structured safety, tolerability, and efficacy assessments (cotinine-confirmed 7-day point prevalence abstinence) were conducted weekly.
There were no serious adverse events. Two participants discontinued bupropion XL due to adverse effects, and none discontinued varenicline. Over the course of treatment, participants receiving varenicline reduced from 14.1 ± 6.3 (mean ± SD) to 0.9 ± 2.1 cigarettes/day (CPD, 4 achieved abstinence), while those receiving bupropion XL reduced from 15.8 ± 4.4 to 3.1 ± 4.0 CPD (2 achieved abstinence).
These preliminary results support the feasibility and safety of conducting adequately powered, placebo-controlled efficacy studies of varenicline and bupropion XL for adolescent smoking cessation.
尽管具有巨大的潜在公共卫生影响，但很少有工作专注于为青少年开发基于证据的戒烟治疗方法，包括药物治疗。以前没有研究探讨过伐伦克林和安非他酮 XL 这两种有前途的潜在药物作为青少年戒烟治疗方法的可行性和安全性。
寻求治疗的年长青少年吸烟者（年龄 15-20 岁）被随机（双盲）分配到伐伦克林（n = 15）或安非他酮 XL（n = 14）组，为期 1 周的滴定和为期 7 周的积极治疗。每周进行结构化的安全性、耐受性和疗效评估（通过可替宁确认的 7 天点患病率戒烟）。
没有严重的不良事件。两名参与者因不良反应而停用安非他酮 XL，没有参与者停用伐伦克林。在治疗过程中，接受伐伦克林治疗的参与者从每天 14.1 ± 6.3（平均值 ± 标准差）减少到每天 0.9 ± 2.1 支香烟（CPD，4 人实现戒烟），而接受安非他酮 XL 治疗的参与者从每天 15.8 ± 4.4 减少到每天 3.1 ± 4.0 CPD（2 人实现戒烟）。
这些初步结果支持对青少年戒烟进行伐伦克林和安非他酮 XL 的充分效力、安慰剂对照疗效研究的可行性和安全性。
